ArticleBreast care (Basel, Switzerland)2017
Application of BI-RADS Descriptors in Contrast-Enhanced Dual-Energy Mammography: Comparison with MRI.
Article in Breast care (Basel, Switzerland), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Inter-reader agreement of the BI-RADS CEM lexicon.European radiology · 2025Article
- Chemical Nose-Based Non-Invasive Detection of Breast Cancer Using Exhaled Breath.Sensors (Basel, Switzerland) · 2025Article
- Lesion Conspicuity in Contrast-Enhanced Mammography: A Retrospective Analysis of Tumor Characteristics.Cancers · 2025Article
- [Use of contrast-enhanced mammography for diagnosis of breast cancer].Radiologie (Heidelberg, Germany) · 2023Review
- Review
- Barriers to Implementation of Contrast-Enhanced Mammography in Clinical Practice:AJR. American journal of roentgenology · 2023Review
- Contrast Enhanced Mammography (CEM) Enhancing Asymmetry: Single-Center First Case Analysis.Diagnostics (Basel, Switzerland) · 2023Article
- Contrast-enhanced mammography-guided biopsy: technical feasibility and first outcomes.European radiology · 2023Article
- [Breast Imaging Reporting and Data System (BI-RADS): Advantages and Limitations].Journal of the Korean Society of Radiology · 2023Review
- Contrast-Enhanced Mammography versus Breast Magnetic Resonance Imaging: A Systematic Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2022Review
- Comparison of Contrast-Enhanced Spectral Mammography and Contrast-Enhanced MRI in Screening Multifocal and Multicentric Lesions in Breast Cancer Patients.Contrast media & molecular imaging · 2022Article
- Incorporating the clinical and radiomics features of contrast-enhanced mammography to classify breast lesions: a retrospective study.Quantitative imaging in medicine and surgery · 2021Article
- Review
- Low-Dose, Contrast-Enhanced Mammography Compared to Contrast-Enhanced Breast MRI: A Feasibility Study.Journal of magnetic resonance imaging : JMRI · 2020Article
- The emerging role of contrast-enhanced mammography.Quantitative imaging in medicine and surgery · 2019Article
- Technique, protocols and adverse reactions for contrast-enhanced spectral mammography (CESM): a systematic review.Insights into imaging · 2019Review
- Classification of contrast-enhanced spectral mammography (CESM) images.International journal of computer assisted radiology and surgery · 2019Article
- Article
- BI-RADS 3: Current and Future Use of Probably Benign.Current radiology reports · 2018Review
- Advanced Imaging for Precision Medicine in Breast Cancer: From Morphology to Function.Breast care (Basel, Switzerland) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundContrast-enhanced (CE) magnetic resonance imaging (MRI) BI-RADS descriptors are used in the evaluation of contrast-enhanced dual-energy mammography (CEDEM) images of mass lesions and are assumed to be applicable. PATIENTS AND
methodsPatients with suspicious mass lesions on mammography (BI-RADS 4 or 5) were included. CEDEM examinations were performed using a modified prototype unit. CE-MRI was performed using a high temporal and high spatial resolution imaging protocol. 2 blinded breast radiologists evaluated all images using criteria related to contrast enhancement intensity and morphology according to the BI-RADS lexicon (5th edition) in 2 sessions. Histopathology was used as the standard of reference.
results11 patients with 5 benign and 6 malignant index lesions were included. Enhancement characteristics were similar in the malignant cases. Enhancement of the benign lesions was moderate on CEDEM and strong on MRI. Discrepancies in the BI-RADS descriptors did not influence the final BI-RADS score. Overall, the BI-RADS assessment was almost identical in all cases. 1 malignant lesion was rated BI-RADS 4 with CEDEM and BI-RADS 5 with MRI, and 1 benign was rated BI-RADS 2 and BI-RADS 1, respectively.
conclusionMRI BI-RADS descriptors of contrast-enhancing lesions can be applied for the morphologic analysis of mass lesions on CEDEM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.